The emergence of tumor resistance to conventional drugs restricts their clinical use. Our team conducts chemical biology strategies and phenotypic screens to identify new drugs with new mechanism of action [1] . Using a cell-based assay that recognizes microtubule polymerization status to screen for chemicals that interact with regulators of microtubule dynamics[2], we have identified Pyr1, a cell permeable inhibitor of LIM Kinase (LIMK), which is the enzyme that phosphorylates and inactivates the actin depolymerizing factor cofilin and controls microtubule dynamics, through a yet unknown mechanism. Thus, LIMK function as a network hub that coordinates actin and microtubule dynamics. Pyr1 inhibition of LIMK caused a microtubule stabilizing effect, and impairs cell movement by deregulating actin dynamics [3] . LIMK is considered as an emerging target for cancer therapy. Moreover, due to their indirect stabilizing effect on microtubules, LIMK inhibitors could represent an attractive alternative strategy for taxane resistant cancers. We have investigated the effect of Pyr1 on breast tumor development and on paclitaxel resistant tumors. On different xenograft cancer models resistant to paclitaxel, Pyr1 shows potent antitumor activity with no detectable undesirable side effects. We have evaluated Pyr1 effects on motility and invasion using intravital microscopy. We found that Pyr1 did not prevent metastases spreading, but promoted a dramatic repression of metastases growth. These results indicate that LIMK inhibitors, such as Pyr1, may represent a pharmacological alternative for the treatment of taxane resistant tumors [4] . Moreover, they could be potent agents to reduce the size of metastases. 
